You are here: Industry Insights > Market News > New Covid-19 treatment drug available for use in Ireland

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

water filter

WATER FILTER FOR WATER PURIFIER

DUST BAG

Small dust filter

HUMIDIFIER FILTER

Oil fume adsorption filter

New Covid-19 treatment drug available for use in Ireland

FirstWordPharmaJanuary 28, 2022

Tag: COVID-19 , Xevudy , antibody

Favorites

Ireland has agreed a supply deal for GlaxoSmithKline's COVID-19 antibody treatment Xevudy (sotrovimab), reported The Irish Times.

The UK drugmaker and its partner Vir Biotechnology agreed a contract last year with the EU to supply up to 220,000 doses of Xevudy for use by member states.

It is authorised for use in over-12s with COVID-19 who do not need supplemental oxygen and who are at greater risk of developing severe illness.

In January, the Irish government agreed to spend €90 million on antiviral and monoclonal antibody treatments made by Pfizer, GlaxoSmithKline and Merck & Co.

Previous:China's Walvax says has most participants for large mRNA COVID vaccine trial

Next:AG Nessel Launches Investigation into Excessive Insulin Prices, Intends to Challenge MSC Decisions Impacting Consumer Protection

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

New Covid-19 treatment drug available for use in Ireland - PharmaSources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

New Covid-19 treatment drug available for use in Ireland

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may like
More>>

New Covid-19 treatment drug available for use in Ireland

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may likeMore>>

You may like
More>>